Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Rating of "Moderate Buy" by Analysts

Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) has received an average rating of "Moderate Buy" from the six research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $10.80.

Separately, HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research report on Wednesday, February 26th.

Regulus Therapeutics Stock Performance

Shares of RGLS traded up $0.02 during mid-day trading on Monday, hitting $1.37. 155,395 shares of the stock were exchanged, compared to its average volume of 527,414. The company has a market cap of $89.74 million, a PE ratio of -1.28 and a beta of 1.58. Regulus Therapeutics has a 52-week low of $0.83 and a 52-week high of $3.79. The firm has a 50-day moving average of $1.30 and a two-hundred day moving average of $1.47.

Insider Buying and Selling

In related news, VP Christopher Ray Aker sold 38,547 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $48,569.22. Following the sale, the vice president now directly owns 54,634 shares of the company's stock, valued at $68,838.84. This represents a 41.37 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Joseph P. Hagan acquired 50,000 shares of the firm's stock in a transaction on Thursday, January 30th. The stock was purchased at an average cost of $1.09 per share, with a total value of $54,500.00. Following the purchase, the chief executive officer now owns 260,808 shares of the company's stock, valued at $284,280.72. The trade was a 23.72 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 223,998 shares of company stock worth $282,237 over the last three months. 4.35% of the stock is owned by insiders.

Remove Ads

Institutional Trading of Regulus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. NEA Management Company LLC bought a new stake in Regulus Therapeutics during the 3rd quarter valued at $10,154,000. Millennium Management LLC lifted its stake in shares of Regulus Therapeutics by 69.7% during the 4th quarter. Millennium Management LLC now owns 2,192,158 shares of the biopharmaceutical company's stock worth $3,464,000 after purchasing an additional 900,743 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Regulus Therapeutics during the third quarter valued at about $1,403,000. Octagon Capital Advisors LP grew its stake in Regulus Therapeutics by 13.7% in the fourth quarter. Octagon Capital Advisors LP now owns 4,848,802 shares of the biopharmaceutical company's stock valued at $7,661,000 after purchasing an additional 585,101 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Regulus Therapeutics during the third quarter valued at about $204,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.